ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Genetics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1659708
Identification and prognostic prediction of high-risk multiple myeloma by exosomal microRNA
Provisionally accepted- 1Sichuan University West China Hospital Department of Hematology, Chengdu, China
- 2Chengdu Shangjin Nanfu Hospital, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Circulating exosomal microRNAs (miRNAs) are gaining traction as novel liquid biopsy biomarkers for the early detection, treatment monitoring, and prognostication of multiple myeloma (MM). Employing RNA sequencing, we identified 20 differentially expressed genes in exosomes isolated from the peripheral blood of 17 newly diagnosed multiple myeloma patients and 8 healthy controls. Utilizing a testing cohort of 60 newly diagnosed MM cases, we developed a diagnostic model based on six miRNAs (hsa-miR-192-5p, hsa-miR-10a-5p, hsa-miR-10b-3p, hsa-miR-148a-3p, hsa-miR-193b-5p, hsa-miR-483-3p) achieving an AUC of 0.94, sensitivity of 0.88, and specificity of 0.94. In a validation cohort of 130 MM patients, we developed a prognostic nomogram that amalgamated the expression levels of three key exosomal miRNAs (hsa-miR-193b-5p, miR-483-3p, and let-7b-5p) with critical clinical variables, which exhibits superior performance compared to the ISS staging
Keywords: exosomal miRNA, Multiple Myeloma, diagnostic, prognostic, liquid biopsy
Received: 07 Jul 2025; Accepted: 12 Sep 2025.
Copyright: © 2025 Ying, Tang, Zhang, Xu, Yang, Liu, Zhong, Wang and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Caigang Xu, Sichuan University West China Hospital Department of Hematology, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.